CRO / CMO Industry Trends NI Company News NI Published Articles NI Calendar of Events NI Media Partners Contact Us 
Pharma Chem Outsourcing 2013
September 16-18 Long Branch, NJ 
Life Science Leader — April 2013 Outsourcing and the oral solid dose: Will challenges lead to new patterns of outsourcing? Life Science Leader — CRO Leadership Awards supplement issue Strategic Outsourcing Often Means Combining Functional and Full-Service CROs 
|
Contract Research & Manufacturing (Americas, Europe, Asia) The contract research and manufacturing market is still a growing segment of the pharmaceutical and biotechnology industry. It is composed of contract manufacturing organizations (CMOs) and contract research organizations (CROs) that provide outsourcing services including drug research, development and manufacturing. Prior to the recent economic downturn, small-to-mid size pharmaceutical and biotechnology sponsors outsourced a greater percentage of their research and manufacturing. Currently, larger sponsors are looking to lower their costs and improve productivity by spinning off or selling their non-core activities such as research and manufacturing. This enables outsourcing providers to garner a greater share of the market and potentially expand their services by acquiring these business segments. Nice Insight's CRO / CMO reports provide business-to-business marketing research covering 300+ contract service providers, which account for an excess 80% of the market revenue*. CROs and CMOs utilize these reports to better understand how they are perceived by the industry, enabling them to customize their messaging to increase the effectiveness of their brand positioning. Biotechnology and pharmaceutical clients use our reports to aid in the screening and selection process for outsourcing partners. Our intelligence is also used as an equity research tool in the finance community. Bio-Partnering Large drug-makers are employing a wide range of strategies to bolster revenues and maintain profitability in the midst of recent patent expirations. As a result, they have started increasing efforts to in-license and partner with R&D therapeutics developed by smaller pharmaceutical and biotechnology firms. In recent years, R&D programs have been reconfigured to focus on areas of proven therapeutic expertise, as well as the growing field of specialty pharmaceuticals. Large drug-makers have made significant new investments in this market, either through outright acquisitions or through in-licensing and partnership deals with smaller biotech firms. Accordingly, Biotech products accounted for 12 of the 27 novel pharmaceuticals and biologics approved by the US Food and Drug Administration (FDA) in 2010. Nice Insight's bio-partnering reports cover the Top 50 biopharmaceutical organizations at the center of this growing licensing network. Our clients use these reports to gauge industry perception and awareness of potential licensing partners for the development and commercialization of new drug therapies. The reports specifically outline the most important characteristics driving the selection of partners, determine perceived industry performance based on these characteristics, and consolidate perceived performance of specific buy-side companies. *Unaudited financial data |
